FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200213505> ?p ?o ?g. }

• W4200213505 abstract "Gout is an inflammatory arthritis resulting from the deposition of monosodium urate crystals in and around joints. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat acute gout. This is an update of a Cochrane Review first published in 2014.To assess the benefits and harms of non-steroidal anti-inflammatory drugs (NSAIDs) (including cyclo-oxygenase-2 (COX-2) inhibitors (COXIBs)) for acute gout.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase for studies to 28 August 2020. We applied no date or language restrictions.We considered randomised controlled trials (RCTs) and quasi-RCTs comparing NSAIDs with placebo or another therapy for acute gout. Major outcomes were pain, inflammation, function, participant-reported global assessment, quality of life, withdrawals due to adverse events, and total adverse events.We used standard methodological procedures as expected by Cochrane.We included in this update 28 trials (3406 participants), including 5 new trials. One trial (30 participants) compared NSAIDs to placebo, 6 (1244 participants) compared non-selective NSAIDs to selective cyclo-oxygenase-2 (COX-2) inhibitors (COXIBs), 5 (712 participants) compared NSAIDs to glucocorticoids, 13 compared one NSAID to another NSAID (633 participants), and single trials compared NSAIDs to rilonacept (225 participants), acupuncture (163 participants), and colchicine (399 participants). Most trials were at risk of selection, performance, and detection biases. We report numerical data for the primary comparison NSAIDs versus placebo and brief results for the two comparisons - NSAIDs versus COX-2 inhibitors and NSAIDs versus glucocorticoids. Low-certainty evidence (downgraded for bias and imprecision) from 1 trial (30 participants) shows NSAIDs compared to placebo. More participants (11/15) may have a 50% reduction in pain at 24 hours with NSAIDs than with placebo (4/15) (risk ratio (RR) 2.7, 95% confidence interval (CI) 1.1 to 6.7), with absolute improvement of 47% (3.5% more to 152.5% more). NSAIDs may have little to no effect on inflammation (swelling) after four days (13/15 participants taking NSAIDs versus 12/15 participants taking placebo; RR 1.1, 95% CI 0.8 to 1.5), with absolute improvement of 6.4% (16.8% fewer to 39.2% more). There may be little to no difference in function (4-point scale; 1 = complete resolution) at 24 hours (4/15 participants taking NSAIDs versus 1/15 participants taking placebo; RR 4.0, 95% CI 0.5 to 31.7), with absolute improvement of 20% (3.3% fewer to 204.9% more). NSAIDs may result in little to no difference in withdrawals due to adverse events (0 events in both groups) or in total adverse events; two adverse events (nausea and polyuria) were reported in the placebo group (RR 0.2, 95% CI 0.0, 3.8), with absolute difference of 10.7% more (13.2% fewer to 38% more). Treatment success and health-related quality of life were not measured. Moderate-certainty evidence (downgraded for bias) from 6 trials (1244 participants) shows non-selective NSAIDs compared to selective COX-2 inhibitors (COXIBs). Non-selective NSAIDs probably result in little to no difference in pain (mean difference (MD) 0.03, 95% CI 0.07 lower to 0.14 higher), swelling (MD 0.08, 95% CI 0.07 lower to 0.22 higher), treatment success (MD 0.08, 95% CI 0.04 lower to 0.2 higher), or quality of life (MD -0.2, 95% CI -6.7 to 6.3) compared to COXIBs. Low-certainty evidence (downgraded for bias and imprecision) suggests no difference in function (MD 0.04, 95% CI -0.17 to 0.25) between groups. Non-selective NSAIDs probably increase withdrawals due to adverse events (RR 2.3, 95% CI 1.3 to 4.1) and total adverse events (mainly gastrointestinal) (RR 1.9, 95% CI 1.4 to 2.8). Moderate-certainty evidence (downgraded for bias) based on 5 trials (712 participants) shows NSAIDs compared to glucocorticoids. NSAIDs probably result in little to no difference in pain (MD 0.1, 95% CI -2.7 to 3.0), inflammation (MD 0.3, 95% CI 0.07 to 0.6), function (MD -0.2, 95% CI -2.2 to 1.8), or treatment success (RR 0.9, 95% CI 0.7 to 1.2). There was no difference in withdrawals due to adverse events with NSAIDs compared to glucocorticoids (RR 2.8, 95% CI 0.5 to 14.2). There was a decrease in total adverse events with glucocorticoids compared to NSAIDs (RR 1.6, 95% CI 1.0 to 2.5).Low-certainty evidence from 1 placebo-controlled trial suggests that NSAIDs may improve pain at 24 hours and may have little to no effect on function, inflammation, or adverse events for treatment of acute gout. Moderate-certainty evidence shows that COXIBs and non-selective NSAIDs are probably equally beneficial with regards to improvement in pain, function, inflammation, and treatment success, although non-selective NSAIDs probably increase withdrawals due to adverse events and total adverse events. Moderate-certainty evidence shows that systemic glucocorticoids and NSAIDs probably are equally beneficial in terms of pain relief, improvement in function, and treatment success. Withdrawals due to adverse events were also similar between groups, but NSAIDs probably result in more total adverse events. Low-certainty evidence suggests no difference in inflammation between groups. Only low-certainty evidence was available for the comparisons NSAID versus rilonacept and NSAID versus acupuncture from single trials, or one NSAID versus another NSAID, which also included many NSAIDs that are no longer in clinical use. Although these data were insufficient to support firm conclusions, they do not conflict with clinical guideline recommendations based upon evidence from observational studies, findings for other inflammatory arthritis, and expert consensus, all of which support the use of NSAIDs for acute gout." @default.
• W4200213505 created "2021-12-31" @default.
• W4200213505 creator A5000282057 @default.
• W4200213505 creator A5015427405 @default.
• W4200213505 creator A5020895407 @default.
• W4200213505 creator A5036470851 @default.
• W4200213505 creator A5073570045 @default.
• W4200213505 creator A5087398493 @default.
• W4200213505 creator A5089158758 @default.
• W4200213505 date "2021-12-09" @default.
• W4200213505 modified "2023-10-17" @default.
• W4200213505 title "Non-steroidal anti-inflammatory drugs for acute gout" @default.
• W4200213505 cites W112609331 @default.
• W4200213505 cites W1565958804 @default.
• W4200213505 cites W1582882063 @default.
• W4200213505 cites W1598577731 @default.
• W4200213505 cites W1714980748 @default.
• W4200213505 cites W181080058 @default.
• W4200213505 cites W181328729 @default.
• W4200213505 cites W1822035430 @default.
• W4200213505 cites W1897990918 @default.
• W4200213505 cites W1959801535 @default.
• W4200213505 cites W1974909863 @default.
• W4200213505 cites W1977521225 @default.
• W4200213505 cites W1979670706 @default.
• W4200213505 cites W1986731057 @default.
• W4200213505 cites W2007189186 @default.
• W4200213505 cites W2009307145 @default.
• W4200213505 cites W200935692 @default.
• W4200213505 cites W2010501723 @default.
• W4200213505 cites W2012920835 @default.
• W4200213505 cites W2013186181 @default.
• W4200213505 cites W2015038423 @default.
• W4200213505 cites W2022708483 @default.
• W4200213505 cites W202378911 @default.
• W4200213505 cites W2036211012 @default.
• W4200213505 cites W2042402327 @default.
• W4200213505 cites W2042612482 @default.
• W4200213505 cites W2043355327 @default.
• W4200213505 cites W2056628234 @default.
• W4200213505 cites W2063567095 @default.
• W4200213505 cites W2071263587 @default.
• W4200213505 cites W2077889976 @default.
• W4200213505 cites W2090888194 @default.
• W4200213505 cites W2092203374 @default.
• W4200213505 cites W2098465485 @default.
• W4200213505 cites W2099748786 @default.
• W4200213505 cites W2108300055 @default.
• W4200213505 cites W2110652539 @default.
• W4200213505 cites W2112391342 @default.
• W4200213505 cites W2118419599 @default.
• W4200213505 cites W2119634110 @default.
• W4200213505 cites W2124881269 @default.
• W4200213505 cites W2129054895 @default.
• W4200213505 cites W2134049088 @default.
• W4200213505 cites W2137400112 @default.
• W4200213505 cites W2137981468 @default.
• W4200213505 cites W2143303524 @default.
• W4200213505 cites W2146982371 @default.
• W4200213505 cites W2151809600 @default.
• W4200213505 cites W2161344815 @default.
• W4200213505 cites W2161715178 @default.
• W4200213505 cites W2215586036 @default.
• W4200213505 cites W2296106507 @default.
• W4200213505 cites W2313473004 @default.
• W4200213505 cites W2335116089 @default.
• W4200213505 cites W2335302945 @default.
• W4200213505 cites W2342181010 @default.
• W4200213505 cites W2353412481 @default.
• W4200213505 cites W2365968878 @default.
• W4200213505 cites W2386328613 @default.
• W4200213505 cites W2396168972 @default.
• W4200213505 cites W2396690745 @default.
• W4200213505 cites W2399617398 @default.
• W4200213505 cites W2411068987 @default.
• W4200213505 cites W2417598945 @default.
• W4200213505 cites W2426678382 @default.
• W4200213505 cites W2546951278 @default.
• W4200213505 cites W2972414225 @default.
• W4200213505 cites W2974082440 @default.
• W4200213505 cites W2974705820 @default.
• W4200213505 cites W2982516776 @default.
• W4200213505 cites W3023256684 @default.
• W4200213505 cites W3046281783 @default.
• W4200213505 cites W415053 @default.
• W4200213505 cites W4211062734 @default.
• W4200213505 cites W4232058719 @default.
• W4200213505 cites W4237101852 @default.
• W4200213505 cites W4239736175 @default.
• W4200213505 doi "https://doi.org/10.1002/14651858.cd010120.pub3" @default.
• W4200213505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34882311" @default.
• W4200213505 hasPublicationYear "2021" @default.
• W4200213505 type Work @default.
• W4200213505 citedByCount "5" @default.
• W4200213505 countsByYear W42002135052022 @default.
• W4200213505 countsByYear W42002135052023 @default.
• W4200213505 crossrefType "journal-article" @default.
• W4200213505 hasAuthorship W4200213505A5000282057 @default.
• W4200213505 hasAuthorship W4200213505A5015427405 @default.
• W4200213505 hasAuthorship W4200213505A5020895407 @default.

• next